CoChat
Sign Up
Cited by 482

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A census of amplified and overexpressed human cancer genes

Santarius, Thomas, Shipley, Janet, Brewer, Daniel, Stratton, Michael R., Cooper, Colin S.·2010·Nature Reviews Cancer
DOI 10.1038/nrc2771
Open this paper in CoChat — free account

Abstract

Integrated genome-wide screens of DNA copy number and gene expression in human cancers have accelerated the rate of discovery of amplified and overexpressed genes. However, the biological importance of most of the genes identified in such studies remains unclear. In this Analysis, we propose a weight-of-evidence based classification system for identifying individual genes in amplified regions that are selected for during tumour development. In a census of the published literature we have identified 77 genes for which there is good evidence of involvement in the development of human cancer.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc2771

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. Bignell GR. et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res. 17, 1296–1303 (2007). · DOI
  2. Savelyeva L. & Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 167, 115–123 (2001). · DOI
  3. Myllykangas S. & Knuutila S. Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett. 232, 79–89 (2006). · DOI
  4. Schwab M. Oncogene amplification in solid tumors. Semin. Cancer Biol. 9, 319–325 (1999). · DOI
  5. Natrajan R. et al. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors. Clin. Cancer Res. 12, 7284–7293 (2006). · DOI
  6. McIntyre A. et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 65, 8085–8089 (2005). · DOI
  7. Fix A. et al. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosom. Cancer 47, 819–834 (2008). · DOI
  8. Weber A, Imisch P, Bergmann E & Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J. Clin. Oncol. 22, 2681–2690 (2004). · DOI
  9. Kaneko S., Ohira M, Nakamura Y, Isogai E, Nakagawara A & Kaneko M. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J. Cancer Res. Clin. Oncol. 133, 185–192 (2007). · DOI
  10. De Preter K. et al. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J. Clin. Oncol. 23, 3167–3168 (2005). · DOI
  11. Rodriguez S. et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 22, 1880–221891 (2003). · DOI
  12. Zafarana G. et al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. Oncogene 22, 7695–7701 (2003). · DOI
  13. Bourdon V. et al. Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res. 62, 6218–6223 (2002).
  14. Ormandy CJ, Musgrove EA, Hui R., Daly RJ & Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 78, 323–335 (2003). · DOI
  15. Albertson DG. Gene amplification in cancer. Trends Genet. 22, 447–455 (2006). · DOI
  16. Cordon-Cardo C. et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54, 794–799 (1994).
  17. Hayward NK. Genetics of melanoma predisposition. Oncogene 22, 3053–3062 (2003). · DOI
  18. Feber A. et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23, 1627–1630 (2004). · DOI
  19. Oeggerli M. et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23, 5616–5623 (2004). · DOI
  20. Kao J. & Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosom. Cancer 45, 761–769 (2006). · DOI
  21. Comoglio PM, Giordano S. & Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Rev. Drug Discov. 7, 504–516 (2008). · DOI
  22. Zender L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253–1267 (2006). · DOI · Paper page
  23. Mass RD. et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240–246 (2005). · DOI
  24. Ray ME. et al. Genomic and expression analysis of the 8p11–12 amplicon in human breast cancer cell lines. Cancer Res. 64, 40–47 (2004). · DOI
  25. Garcia MJ. et al. A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes. Oncogene 24, 5235–5245 (2005). · DOI
  26. Reis-Filho JS. et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12, 6652–6662 (2006). · DOI
  27. Campbell PJ. et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nature Genet. 40, 722–729 (2008). · DOI
  28. Sugawa N., Ekstrand AJ, James CD & Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl Acad. Sci. USA 87, 8602–8606 (1990). · DOI · Paper page
  29. Weber-Hall S. et al. Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. Genes Chromosom. Cancer 17, 7–13 (1996). · DOI
  30. Nikolsky Y. et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 68, 9532–9540 (2008). · DOI

Cited by

Sorted by citations

Metadata

Authors
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R., & Cooper, C. S.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2010-01
Volume
10
Issue
1
Pages
59-64
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc2771
Cited by
482
References
2
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review